GJA8: A Potential Drug Target for Neurodegenerative Disorders

Target Name: GJA8

NCBI ID: G2703

GJA8: A Potential Drug Target for Neurodegenerative Disorders

GJA8 (Connexin-50) is a protein that is expressed in the brain and is involved in the regulation of cell types and their functions. It is a potential drug target and has been identified as a biomarker for various neurological disorders.

GJA8 is a member of the Connexin family of transmembrane proteins, which are involved in the regulation of tight junctions, which are a type of cell-cell barrier that helps to maintain the integrity of the blood-brain barrier. The Connexin family has been implicated in a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

GJA8 is expressed in various tissues and cell types in the brain, including neurons, glial cells, and pericytes. It is involved in the regulation of cell types and their functions, including the maintenance of neuronal stem cells, the generation of new neurons, and the regulation of neurotransmitter release.

GJA8 has also been shown to play a role in the regulation of pain perception and the modulation of pain signaling. It is involved in the regulation of the neurotransmitter GABA, which is involved in the inhibition of pain signaling. Additionally, GJA8 has been shown to play a role in the regulation of the immune response, specifically in the modulation of inflammation.

GJA8 is also a potential biomarker for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The accumulation of GJA8 in these disorders has been shown to be associated with the progression of the disease. For example, studies have shown that the levels of GJA8 are significantly increased in the brains of individuals with Alzheimer's disease compared to those without the disease.

In addition to its potential clinical applications, GJA8 is also a valuable research tool for the study of neurodegenerative disorders. The regulation of GJA8 has been shown to be disrupted in a number of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This suggests that GJA8 may be a useful target for the development of new treatments for these disorders.

GJA8 is also a potential drug target for the treatment of other neurological disorders, including pain perception and inflammation. The regulation of GJA8 has been shown to play a role in the modulation of pain signaling and the regulation of inflammation, making it a potential target for the treatment of pain and inflammation.

In conclusion, GJA8 is a protein that is involved in the regulation of cell types and their functions in the brain. Its potential clinical applications include the treatment of neurodegenerative disorders and the modulation of pain and inflammation. Further research is needed to fully understand the role of GJA8 in these processes and to develop new treatments for the treatment of these disorders.

Protein Name: Gap Junction Protein Alpha 8

Functions: Structural component of eye lens gap junctions (PubMed:18006672, PubMed:19756179). Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane (By similarity). Small molecules and ions diffuse from one cell to a neighboring cell via the central pore (PubMed:18006672, PubMed:19756179)

More Common Targets